100s of titles, one news app for just $10 a month.
Dive Deeper:
Kymera Therapeutics's Return On Capital Employed Insights
Benzinga Pro data, Kymera Therapeutics (NASDAQ:KYMR) reported Q1 sales of $9.62 million. Earnings fell to a loss of $36.68 million,…
PTC Therapeutics's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, PTC Therapeutics's (NASDAQ:PTCT) reported sales totaled $148.74 million. Despite a 11.54% increase…
Sage Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Sage Therapeutics's (NASDAQ:SAGE) reported sales totaled $1.58 million. Despite a 2.13% increase…
Workiva's Return On Capital Employed Insights
Benzinga Pro data, Workiva (NYSE:WK) reported Q1 sales of $129.67 million. Earnings fell to a loss of $18.49 million, resulting…
One subscription that gives you access to news from hundreds of sites
CytoSorbents's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, CytoSorbents's (NASDAQ:CTSO) reported sales totaled $8.69 million. Despite a 3.66% increase in…
Apollo Endosurgery's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Apollo Endosurgery's (NASDAQ:APEN) reported sales totaled $16.66 million. Despite a 19.14% increase…
Get all your news in one place
Latest Business news:
World’s top fertiliser maker sees two years of high prices
In more bad news for farmers, a fertiliser that's key for crop production across the world will remain expensive for…
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
What will happen to the $136 million live sheep industry now Labor has won the federal election?
Farmers are waiting nervously to hear whether Labor will follow through on an election pledge to ban live sheep exports,…
To use rather than collect, the second coming of NFTs
New York (AFP) - NFTs have been called everything from fads to outright scams, but early adopters see a future…
The only way is up for NZ cash rate
Mortgage holders in New Zealand are bracing themselves for another cash-rate hit from the Reserve Bank.
Quality assurance workers at Activision Blizzard subsidiary unionize, a first at a major US gaming company
A small group of quality assurance workers at an Activision Blizzard-owned game studio have unionized, marking the arrival of the…
From analysis to good news, read the world’s best news in one place
‘Buy now, pay later’ leader Klarna slashes staff numbers as the prospect of rate increases push up its borrowing costs
Swedish ‘buy now, pay later’ company Klarna Bank saw its borrowing costs climb to their highest level on record as…
As Melbourne's night-life recovers from COVID, a liquor licence freeze brought in 13 years ago is under the microscope
The state government says the pause on the granting of new liquor licences will remain in place until June 2023.

Esperion Therapeutics's Return On Capital Employed Insights

By Benzinga Insights

According to Benzinga Pro data, during Q1, Esperion Therapeutics (NASDAQ:ESPR) posted sales of $18.84 million. Earnings were up 12.88%, but Esperion Therapeutics still reported an overall loss of $56.73 million. Esperion Therapeutics collected $15.40 million in revenue during Q4, but reported earnings showed a $65.12 million loss.

What Is ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q1, Esperion Therapeutics posted an ROCE of 0.23%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Esperion Therapeutics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For Esperion Therapeutics, the positive return on capital employed ratio of 0.23% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

Analyst Predictions

Esperion Therapeutics reported Q1 earnings per share at $-0.93/share, which beat analyst predictions of $-1.04/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
Kymera Therapeutics's Return On Capital Employed Insights
Benzinga Pro data, Kymera Therapeutics (NASDAQ:KYMR) reported Q1 sales of $9.62 million. Earnings fell to a loss of $36.68 million,…
PTC Therapeutics's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, PTC Therapeutics's (NASDAQ:PTCT) reported sales totaled $148.74 million. Despite a 11.54% increase…
Sage Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Sage Therapeutics's (NASDAQ:SAGE) reported sales totaled $1.58 million. Despite a 2.13% increase…
Workiva's Return On Capital Employed Insights
Benzinga Pro data, Workiva (NYSE:WK) reported Q1 sales of $129.67 million. Earnings fell to a loss of $18.49 million, resulting…
One subscription that gives you access to news from hundreds of sites
CytoSorbents's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, CytoSorbents's (NASDAQ:CTSO) reported sales totaled $8.69 million. Despite a 3.66% increase in…
Apollo Endosurgery's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Apollo Endosurgery's (NASDAQ:APEN) reported sales totaled $16.66 million. Despite a 19.14% increase…
Get all your news in one place